MarketBeat Provides Analyst Ratings and Financial Tracking for Recursion Pharmaceuticals
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
MarketBeat has begun providing analyst ratings for Recursion Pharmaceuticals. The ratings are part of a larger comparison between Recursion Pharmaceuticals and Bicycle Therapeutics, two healthcare companies. The comparison covers institutional ownership, insider ownership, volatility, profitability, and valuation.
From dailypolitical.com
Why it matters
The reports detail that 89.1% of Recursion Pharmaceuticals shares are held by institutional investors, while 6.7% are held by company insiders. The comparison also notes that Recursion Pharmaceuticals has a beta of 1.07, indicating its stock price is 7% more volatile than the S&P 500.
From dailypolitical.com
Who's involved
- MarketBeatAmerican personal finance blog providing analyst ratings and market data.
- Recursion (United States)Company whose financial performance and analyst ratings are being tracked.
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Recursion (United States)
company in Salt Lake City, United States
Related events
- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- MarketBeat provided consensus rating data for Rectitude Holdings Ltd, a company based in Singapore.
- Recursion Pharmaceuticals is listed on Nasdaq, and BioCardia, Inc. is a company developing therapeutics in the United States.
- MarketBeat provides ratings for listed companies.
- MarketBeat has released its consensus rating and target price for Sunshine Biopharma, Inc.